

## **HHS Public Access**

Author manuscript

J Invest Dermatol. Author manuscript; available in PMC 2014 October 01.

Published in final edited form as: *J Invest Dermatol.* 2014 April ; 134(4): 1141–1142. doi:10.1038/jid.2013.464.

# Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990–2009

Sultan A. Mirzoyev<sup>1</sup>, Adam G. Schrum<sup>2</sup>, Mark D.P. Davis<sup>1</sup>, and Rochelle R. Torgerson<sup>1,\*</sup> <sup>1</sup>Division of Clinical Dermatology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA <sup>2</sup>Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA

### Letter

Alopecia Areata (AA) is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown (Gilhar *et al.*, 2012). The scalp is most commonly involved in clinically treated AA, but any hair-bearing surface of the body may be affected (Wasserman *et al.*, 2007). Males and females of any age and hair color can have AA (Finner, 2011; Kyriakis *et al.*, 2009). According to the First National Health and Nutrition Examination Survey conducted in the early 1970s, AA is fairly common; it was estimated to affect about 2 of every 1,000 people in the United States (Safavi, 1992). Dermatologists encounter AA in 0.7% to 4.0% of their patient populations (Price, 1991; Sharma *et al.*, 1996; Tan *et al.*, 2002). A previous study reported by Mayo Clinic and National Institutes of Health (Safavi *et al.*, 1995) showed that the overall incidence of AA in Olmsted County, Minnesota, was 20.2 per 100,000 person-years from 1975 through 1989. A similar incidence rate for both sexes with a lifetime risk of 1.7% was observed.

The purpose of the current study was to continue the previous analysis and document the most current lifetime incidence risk of AA. Clinical data accessed via the Rochester Epidemiology Project (REP) provided a retrospective review of all patients resident in Olmsted County, Minnesota, that were newly diagnosed with AA from 1990 through 2009. Of 530 qualifying patients, the mean age at diagnosis was 33.6 years (median, 33 years; range, 0–90 years). Additional features for the study cohort are summarized in Table 1. The mean age at diagnosis of AA for males was 31.5 years (median, 31 years; range, 0.5–80 years); for females, it was 36.2 years (median, 36.4 years; range, 1.8–90.7 years).

As shown in Table 2, the age- and sex-adjusted incidence of AA was 20.9 per 100,000 person-years (95% CI, 19.1–22.6). Cumulative AA incidence increased almost linearly with age (0.3%, 20 years; 0.6%, 30 years; 0.8%, 40 years; 1.1%, 50 years; 1.4%, 60 years), while

#### <u>Conflict of Interests</u> The authors declare no conflict of interests.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial\_policies/license.html#terms

<sup>\*</sup>Address correspondence to: Rochelle R. Torgerson, MD/PhD, Division of Clinical Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, Torgerson.rochelle@mayo.edu.

Mirzoyev et al.

cumulative lifetime incidence was 2.1%. Age-adjusted incidence was 21.3 per 100,000 person-years (95% CI, 18.8–23.9) for females and 20.2 per 100,000 person-years (95% CI, 17.7–22.6) for males (no significant difference, P = 0.77), supporting the observation that both females and males display similar susceptibility to AA.

At 2.1%, the cumulative lifetime incidence of AA from this recent 20-year period (1990–2009) was slightly higher than 1.7% observed in the older study (years 1975–1989) (Safavi *et al.*, 1995). Similarly, REP data analyzed in studies of other autoimmune-associated diseases have shown that incidence of rheumatoid arthritis (Myasoedova *et al.*, 2010) and systemic lupus erythematosis (Uramoto *et al.*, 1999) have also increased in the region in recent years. These data do not refute the hypothesis that autoimmune disease incidence may be rising, generally.

The current study also confirms that AA does not exhibit a gender bias (Muller and Winkelmann, 1963). Although some studies have reported AA to be slightly more common in females (Goh *et al.*, 2006; Kyriakis *et al.*, 2009; Tan *et al.*, 2002), such findings might be attributable to a greater cultural awareness of and sensitivity to hair loss among females that prompts them to seek medical attention. Interestingly, in Turkey, a higher male: female ratio (1.6:1) was reported for patients with AA (Kavak *et al.*, 2008). The authors explained the likely artificial skew toward male patients in the context of religious practices and suggested that the headscarves worn by women may have allowed some to avoid seeking medical attention for hair loss. The predominantly white patient population in the current study is reflective of the geographic race distribution and is not a sign of racial differences in AA prevalence. In conclusion, we assessed the incidence of AA in Olmsted County, Minnesota, during a recent 20-year period (1990–2009), and found that the lifetime incidence risk was 2.1%.

#### Methods

#### **Clinical Setting**

This study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center. The REP medical records system links information from all health care providers in Olmsted County, Minnesota. It includes medical records for all residents of the county, regardless of where care was received in the county. The relative geographic isolation of Olmsted County residents from other medical institutions provides a unique opportunity to conduct population-based analyses (St Sauver *et al.*, 2012).

#### **Patient Selection**

The REP databank was used to identify Olmsted County residents with their first lifetime diagnosis of AA established from 1990 through 2009. Medical records of identified patients were reviewed and data were abstracted. Each diagnosis was validated by a physician and documented in the medical record.

J Invest Dermatol. Author manuscript; available in PMC 2014 October 01.

#### **Statistical Methods**

Incidence rates per 100,000 person-years were calculated using incident cases of AA as the numerator and age- and sex-specific estimates of the county population as the denominator. The populations at risk for the years 1990–2000 were estimated using census data from 1990 and 2000, with linear interpolation for intercensal years. The populations at risk for the years 2001–2009 were obtained from US Intercensal Estimates (United States Census Bureau). Because the population of Olmsted County is nearly all white, incidence rates were directly age- and sex-adjusted to the structure of the 2000 US white population. Incident cases were grouped on the basis of age at diagnosis (0–9, 10–19, 20–29, 30–39, 40–49, 50–59, and 60 years) and year of diagnosis (1990–1994–1995–1999–2000–2004, and 2005–2009). The relationships of age at diagnosis, sex, and year of diagnosis with the incidence of AA were assessed by fitting Poisson regression models using the SAS procedure GENMOD (SAS Institute Inc). *P* values less than 0.05 were considered statistically significant.

#### Acknowledgments

The Rochester Epidemiology Project (REP) is supported by the National Institute on Aging of the National Institutes of Health (R01AG034676). We are indebted to Christine M. Lohse, MS, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, for assistance with statistical analysis.

### Abbreviations

AA	Alopecia Areata	

**REP** Rochester Epidemiology Project

#### References

- Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011; 24:348–54. [PubMed: 21689244]
- Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012; 366:1515–25. [PubMed: 22512484]
- Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006; 20:1055–60. [PubMed: 16987257]
- Kavak A, Yesildal N, Parlak AH, Gokdemir G, Aydogan I, Anul H, et al. Alopecia areata in Turkey: demographic and clinical features. J Eur Acad Dermatol Venereol. 2008; 22:977–81. [PubMed: 18384559]
- Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E. Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol. 2009; 23:572–3. [PubMed: 18771448]
- Muller SA, Winkelmann RK. Alopecia Areata. an Evaluation of 736 Patients. Arch Dermatol. 1963; 88:290–7. [PubMed: 14043621]
- Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010; 62:1576–82. [PubMed: 20191579]
- Price VH. Alopecia areata: clinical aspects. J Invest Dermatol. 1991; 96:68S. [PubMed: 2022874]
- Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol. 1992; 128:702. [PubMed: 1575541]
- Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd . Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995; 70:628–33. [PubMed: 7791384]

J Invest Dermatol. Author manuscript; available in PMC 2014 October 01.

- Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996; 35:22–7. [PubMed: 8838924]
- St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Pankratz JJ, Brue SM, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012; 41:1614–24. [PubMed: 23159830]
- Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians. Int J Dermatol. 2002; 41:748–53. [PubMed: 12452996]
- Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum. 1999; 42:46–50. [PubMed: 9920013]
- Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007; 46:121–31. [PubMed: 17269961]

Author Manuscript

Author Manuscript

Table 1

Patient Characteristics (N=530)

Year of diagnosis (n=530)	
1990–1994	90 (17)
1995–1999	120 (23)
2000–2004	149 (28)
2005-2009	171 (32)
Female sex	271 (51)
Diagnosis	
Dermatologist	460 (87)
Nondermatologist physician	70 (13)
Biopsy confirmation <sup>a</sup>	73 (14)
Race (n=482)	
White	423 (88)
Asian	30 (6)
Black	18 (4)
Hispanic or Latino	11 (2)

J Invest Dermatol. Author manuscript; available in PMC 2014 October 01.

Author Manuscript

Table 2

Mirzoyev et al.

Incidence of AA in Olmsted County, Minnesota, 1990–2009, Stratified by Age and Sex

	Females		Males		mor	
Age at Diagnosis	No. of Patients	Rate <sup>a</sup>	Rate <sup>a</sup> No. of Patients	Rate <sup>a</sup>	No. of Patients	Rate <sup>a</sup>
6-0	27	14.9	32	16.7	59	15.8
10–19	33	19.4	26	14.6	59	17.0
20–29	49	27.1	58	32.9	107	29.9
30–39	45	23.1	73	37.2	118	30.1
40-49	52	27.1	36	19.2	88	23.2
50-59	35	25.4	24	18.1	59	21.8
60	30	14.3	10	6.4	40	10.9
Total	271	$21.3^{b}$	259	$20.2^{b}$	530	20.9 <sup>c</sup>

<sup>c</sup>Incidence rates per 100,000 person-years were age- and sex-adjusted to the 2000 US white population.